La chaîne d'options affiche les données clés des options sur actions de Lexaria Bioscience à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Lexaria Bioscience..

Lexaria Bioscience (NASDAQ:LEXX) Stock, Chaîne d'Options

LEXARIA BIOSCIENCE CORP

Lexaria Bioscience

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Lexaria Bioscience Corp

News

Press Releases

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Offerings

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Penny Stocks

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Provides Strategic Update

LEXX

LEXXW

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

Biofrontera

Cingulate

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Cocrystal Pharma

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Curanex Pharmaceuticals Inc - Common Stock

Curanex Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Gelteq

Hoth Therapeutics

IM Cannabis

Incannex Healthcare

Lipocine

Lyra Therapeutics

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

ProPhase Labs

Pulmatrix

Q/C Technologies

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

SenesTech

Traws Pharma

TherapeuticsMD

cbdMD

HC Wainwright & Co.

Maxim Group

Comments

Lexaria Bioscience

Lexaria Bioscience (LEXX) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL